Trial · NCT03182907
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Area Under the Concentration-Time Curve of Bezlotoxumab From Time 0 to Infinity (AUC0-inf) | Bezlotoxumab: Cohort 1 (12 to <18 Years Age) | 56100 | 95% Confidence Interval 49400 to 63700 | hr*ug/mL | |
| Area Under the Concentration-Time Curve of Bezlotoxumab From Time 0 to Infinity (AUC0-inf) | Bezlotoxumab: Cohort 2 (1 to <12years of Age) | 43200 | 95% Confidence Interval 38900 to 47900 | hr*ug/mL | |
| Percentage of Participants Who Experienced an Adverse Event (AE) | Bezlotoxumab | 88.8 | Percentage of participants | ||
| Percentage of Participants Who Experienced an Adverse Event (AE) | Placebo | 94.4 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Due to an AE | Bezlotoxumab | 0 | Percentage of participants | ||
| Percentage of Participants Who Discontinued Study Due to an AE | Placebo | 0 | Percentage of participants | ||
| Percentage of Participants Who Had a Clostridium Difficile Infection (CDI) Recurrence | Bezlotoxumab | 11.2 | Percentage of participants | ||
| Percentage of Participants Who Had a Clostridium Difficile Infection (CDI) Recurrence | Placebo | 14.7 | Percentage of participants | ||
| Percentage of Participants Who Had a Sustained Clinical Response (SCR) | Bezlotoxumab | 83.7 | Percentage of participants | ||
| Percentage of Participants Who Had a Sustained Clinical Response (SCR) | Placebo | 82.9 | Percentage of participants | ||
| Percentage of High-Risk Participants Who Experienced a CDI Recurrence | Bezlotoxumab | 12.1 | Percentage of participants | ||
| Percentage of High-Risk Participants Who Experienced a CDI Recurrence | Placebo | 15.2 | Percentage of participants | ||
| Percentage of High-Risk Participants Who Experienced a SCR | Bezlotoxumab | 82.5 | Percentage of participants | ||
| Percentage of High-Risk Participants Who Experienced a SCR | Placebo | 82.4 | Percentage of participants | ||
| Percentage of Participants Who Experienced One or More Infusion Related Reaction | Bezlotoxumab | 0.93 | Percentage of participants | ||
| Percentage of Participants Who Experienced One or More Infusion Related Reaction | Placebo | 2.78 | Percentage of participants | ||
| Percentage of Participants Who Had Positive Antibodies to Bezlotoxumab | Bezlotoxumab: Cohort 1 (12 to <18 Years Age) | 2.4 | Percentage of participants | ||
| Percentage of Participants Who Had Positive Antibodies to Bezlotoxumab | Bezlotoxumab: Cohort 2 (1 to <12 Years of Age) | 1.7 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03182907/results